Abstract
Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 830-841 |
| Number of pages | 12 |
| Journal | Multiple Sclerosis |
| Volume | 22 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 2015 |
Fingerprint
Keywords
- Health-related quality of life
- Multiple sclerosis
- Neuro-QOL
- Patient-reported outcomes
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
}
Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis. / Miller, Deborah M.; Bethoux, Francois; Victorson, David; Nowinski, Cindy J.; Buono, Sarah; Lai, Jin Shei; Wortman, Katy; Burns, James L.; Moy, Claudia; Cella, David.
In: Multiple Sclerosis, Vol. 22, No. 6, 01.01.2015, p. 830-841.Research output: Contribution to journal › Article
TY - JOUR
T1 - Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis
AU - Miller, Deborah M.
AU - Bethoux, Francois
AU - Victorson, David
AU - Nowinski, Cindy J.
AU - Buono, Sarah
AU - Lai, Jin Shei
AU - Wortman, Katy
AU - Burns, James L.
AU - Moy, Claudia
AU - Cella, David
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.
AB - Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.
KW - Health-related quality of life
KW - Multiple sclerosis
KW - Neuro-QOL
KW - Patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85016184031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016184031&partnerID=8YFLogxK
U2 - 10.1177/1352458515599450
DO - 10.1177/1352458515599450
M3 - Article
C2 - 26238464
AN - SCOPUS:85016184031
VL - 22
SP - 830
EP - 841
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 6
ER -